Company to participate in Live Virtual Investor Closing Bell segment today, April 16 th at 4:00 PM ET ; Register for the event here OCALA, Fla., April 16, 2026 (GLOBE NEWSWIRE) --...
OCALA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today advised that its audited consolidated financial statements for the...
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, April 16 th at 4:00 PM ET Register for the event here OCALA, Fla., April 09, 2026 (GLOBE...
Acquisition launches accesso Intelligence SM , connecting guest and operator data, insight and action across the entire operation
Acquisition launches accesso Intelligence SM , connecting guest and operator data, insight and action across the entire operation
OCALA, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Japan Patent Office has fully approved a Japanese...
OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...
OCALA, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...
OCALA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced an agreement with the PPD™ clinical research business...
OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...